1. Repository of OAI
  2. ΑΠΟΘΕΤΗΡΙΟ "ΟΛΥΜΠΙΑΣ"
  3. Σχολή Επιστημών Υγείας
  4. Τμήμα Ιατρικής
  5. Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ
Ελληνικά   English  
Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/24131
Full metadata record
DC FieldValueLanguage
dc.contributor.authorGiannakopoulos, X.en
dc.contributor.authorBaltogiannis, D.en
dc.contributor.authorGiannakis, D.en
dc.contributor.authorTasos, A.en
dc.contributor.authorSofikitis, N.en
dc.contributor.authorCharalabopoulos, K.en
dc.contributor.authorEvangelou, A.en
dc.date.accessioned2015-11-24T19:38:17Z-
dc.date.available2015-11-24T19:38:17Z-
dc.identifier.issn0741-238X-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/24131-
dc.rightsDefault Licence-
dc.subjectbenign prostatic hyperplasiaen
dc.subjectpharmacotherapyen
dc.subjectserenoa repensen
dc.subjectlipidosterolic extracten
dc.subjectlower urinary tract symptomsen
dc.subjectphytotherapyen
dc.subjecturinary-tract symptomsen
dc.subjectepidermal growth-factoren
dc.subjectquality-of-lifeen
dc.subjectpermixon(r)en
dc.subjectfinasterideen
dc.subjectefficacyen
dc.subjectmetaanalysisen
dc.subjecttolerabilityen
dc.subjectobstructionen
dc.subjecthypertrophyen
dc.titleThe lipidosterolic extract of Serenoa repens in the treatment of benign prostatic hyperplasia: A comparison of two dosage regimensen
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.secondary<Go to ISI>://000181352900005-
heal.identifier.secondaryhttp://www.springerlink.com/content/1465112061318671/fulltext.pdf-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.publicationDate2002-
heal.abstractThis 6-month double-blind, randomized, parallel-group study compared two dose regimens of Libeprosta(R), the lipidosterolic extract of Serenoa repens in 100 male outpatients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (BPH). The patients received two 80-mg tablets twice daily or two 80-mg tablets three times daily. Baseline evaluations included maximum and mean urinary flow, rates, postvoid residual urine volume, and International Prostate Symptom Score (I-PSS) total and quality-of-life scores. Both regimens significantly reduced the I-PSS mean total score from baseline values (P<.001); improvements achieved statistical significance after month 3 and were maintained for the duration of the study. Significant improvements from baseline also occurred in quality-of-life scores, maximum and mean urinary flow rates, and residual urine volume (P<.05). The decrease in residual urine with both regimens was highly significant (P<.001). No significant differences in efficacy were noted between the two dose groups, and no treatment-related complications or clinical adverse events occurred. In this clinical study, the lipiclosterolic extract of Serenoa repens was a well-tolerated agent that may significantly improve lower urinary tract symptoms and flow measurements in men with BPH.en
heal.journalNameAdv Theren
heal.journalTypepeer-reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ

Show simple item record
Files in This Item:
File Description SizeFormat 
Giannakopoulos-2002-The lipidosterolic e.pdf120.84 kBAdobe PDFView/Open    Request a copy
Show simple item record  


This item is licensed under a Creative Commons License Creative Commons